Registers Resale of 101.7M Shares for $36M Equity Line, Signaling Massive Dilution
SNYR is trading near its 52-week low of $0.27 (4.5% above the low) on light trading volume (0.4× avg).
Summary
Synergy CHC Corp. registered 101.7 million shares for resale, primarily tied to a $36 million equity line of credit, indicating a potential dilution of over 681% for existing shareholders amidst ongoing financial distress.
Key Events · Financing and Capital Events · SNYR
-
Registration of 101.7 Million Shares for Resale
The company filed an S-1 to register 101,710,000 shares of common stock for resale by Hudson Global Ventures, LLC. These shares include 100,000,000 ELOC Shares, 1,540,000 Warrant Shares, and 170,000 Existing Shares.
-
Equity Line of Credit (ELOC) Details
The registered shares are primarily associated with a $36 million Equity Line of Credit (ELOC) established on May 8, 2026. The company has the right, but not the obligation, to sell shares to the Selling Stockholder at a discounted market price to draw funds.
-
Extreme Potential Dilution
If all 101,540,000 new shares (ELOC and Warrant Shares) are issued, it would represent a dilution of approximately 681% of the 14,899,883 shares outstanding as of May 14, 2026. This is a highly dilutive offering.
-
Shareholder Approval for Issuance Cap
The company requires shareholder approval to issue shares exceeding 19.99% of its outstanding common stock under the ELOC Purchase Agreement. A recent PRE 14A filing indicated the company is seeking approval for a highly dilutive equity plan expansion.
Analysis · SNYR · Life Sciences
Synergy CHC Corp. has filed an S-1 registration statement for the resale of up to 101,710,000 shares of common stock by Hudson Global Ventures, LLC. These shares are primarily linked to a previously announced $36 million Equity Line of Credit (ELOC) and associated warrants. While the company will not receive proceeds from the resale, it may draw up to $36 million from the ELOC by issuing shares at a discounted market price. This registration, following the recent announcement of the ELOC, formalizes the potential for extreme dilution. If all shares registered for resale are issued, it represents a potential dilution of over 681% of the company's currently outstanding shares. This substantial capital raise, at discounted prices and near 52-week lows, is critical for the company's liquidity given its recent history of significant net losses, material weaknesses, and a mandatory equity raise condition on its term loan. The company is also seeking shareholder approval to issue shares beyond a 19.99% cap, indicating an intent to fully utilize this highly dilutive financing mechanism.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 48.6% of the 216 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.05%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNYR was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.27 to $4.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.